VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Maurizio Martini, Ivana de Pascalis, Quintino Giorgio D'Alessandris, Vincenzo Fiorentino, Francesco Pierconti, Hany El Sayed Marei, Lucia Ricci-Vitiani, Roberto Pallini, Luigi Maria Larocca

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.

Original languageEnglish
Article number553
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - May 10 2018

Fingerprint

Glioblastoma
Vascular Endothelial Growth Factor A
Biomarkers
Therapeutics
Protein Isoforms
Heterografts
Nude Rats
Brain
Tumor Burden
Bevacizumab

Keywords

  • Antiangiogenetic-therapy
  • Recurrent glioblastoma
  • Target therapy
  • VEGF isoforms

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. / Martini, Maurizio; de Pascalis, Ivana; D'Alessandris, Quintino Giorgio; Fiorentino, Vincenzo; Pierconti, Francesco; Marei, Hany El Sayed; Ricci-Vitiani, Lucia; Pallini, Roberto; Larocca, Luigi Maria.

In: BMC Cancer, Vol. 18, No. 1, 553, 10.05.2018.

Research output: Contribution to journalArticle

@article{90f214eee37b49519bd5e51b9a44b322,
title = "VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma",
abstract = "Background: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.",
keywords = "Antiangiogenetic-therapy, Recurrent glioblastoma, Target therapy, VEGF isoforms",
author = "Maurizio Martini and {de Pascalis}, Ivana and D'Alessandris, {Quintino Giorgio} and Vincenzo Fiorentino and Francesco Pierconti and Marei, {Hany El Sayed} and Lucia Ricci-Vitiani and Roberto Pallini and Larocca, {Luigi Maria}",
year = "2018",
month = "5",
day = "10",
doi = "10.1186/s12885-018-4442-2",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

AU - Martini, Maurizio

AU - de Pascalis, Ivana

AU - D'Alessandris, Quintino Giorgio

AU - Fiorentino, Vincenzo

AU - Pierconti, Francesco

AU - Marei, Hany El Sayed

AU - Ricci-Vitiani, Lucia

AU - Pallini, Roberto

AU - Larocca, Luigi Maria

PY - 2018/5/10

Y1 - 2018/5/10

N2 - Background: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.

AB - Background: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.

KW - Antiangiogenetic-therapy

KW - Recurrent glioblastoma

KW - Target therapy

KW - VEGF isoforms

UR - http://www.scopus.com/inward/record.url?scp=85046630127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046630127&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4442-2

DO - 10.1186/s12885-018-4442-2

M3 - Article

C2 - 29747600

AN - SCOPUS:85046630127

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 553

ER -